Evidence map›Paper›PMID 36080421›Full record

ArticleMolecules (Basel, Switzerland)2022

A Critical Evaluation of Terpenoid Signaling at Cannabinoid CB1 Receptors in a Neuronal Model.

Michaela Dvorakova, Sierra Wilson, Wesley Corey, Jenna Billingsley, Anaëlle Zimmowitch, Joye Tracey, Alex Straiker, Ken Mackie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michaela DvorakovaGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.ORCID 0000-0003-3002-8568
Sierra WilsonGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Wesley CoreyGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Jenna BillingsleyGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Anaëlle ZimmowitchGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Joye TraceyGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Alex StraikerGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Ken MackieGill Center for Molecular Bioscience, Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.ORCID 0000-0001-8501-6199
Indiana University Bloomington · US

Funding

Neuronal cannabinoidsR01DA011322 · NIDA · UNIVERSITY OF WASHINGTON · PI MACKIE, KENNETH · 1998 to 2014
$3.4M
Cannabinoid Modulation of Cell FunctionK05DA021696 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI MACKIE, KENNETH · 2007 to 2017
$1.3M
NIDA NIH HHS K05 DA021696NIDA NIH HHS R01 DA011322NIH HHS DA011322 , DA021696
6 · The paper itself

Abstract

In addition to phytocannabinoids, cannabis contains terpenoids that are claimed to have a myriad of effects on the body. We tested a panel of five common cannabis terpenoids, myrcene, linalool, limonene, α-pinene and nerolidol, in two neuronal models, autaptic hippocampal neurons and dorsal root ganglion (DRG) neurons. Autaptic neurons express a form of cannabinoid CB1 receptor-dependent retrograde plasticity while DRGs express a variety of transient receptor potential (TRP) channels. Most terpenoids had little or no effect on neuronal cannabinoid signaling. The exception was nerolidol, which inhibited endocannabinoid signaling. Notably, this is not via inhibition of CB1 receptors but by inhibiting some aspect of 2-arachidonoylglycerol (2-AG) production/delivery; the mechanism does not involve reducing the activity of the 2-AG-synthesizing diacylglycerol lipases (DAGLs). Nerolidol was also the only terpenoid that activated a sustained calcium response in a small (7%) subpopulation of DRGs. In summary, we found that only one of five terpenoids tested had notable effects on cannabinoid signaling in two neuronal models. Our results suggest that a few terpenoids may indeed interact with some components of the cannabinoid signaling system and may therefore offer interesting insights upon further study.

Indexed as

CannabinoidsCannabisHallucinogensCannabinoid Receptor AgonistsEndocannabinoidsHippocampusNeuronsReceptor, Cannabinoid, CB1Receptors, CannabinoidTerpenesCannabinoid Receptor AgonistsCannabinoidsEndocannabinoidsHallucinogensReceptor, Cannabinoid, CB1Receptors, CannabinoidTerpenescannabinoidcannabisCB1G protein-coupled receptorterpeneterpenoid

Identifiers

PMID36080421
PMCPMC9457791
OpenAlexW4295083872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.